Search clinical trials for: QL1701

Total 144 results

Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Tumor

China
Second Affiliated Hospital, School of Medicine,...
Shanghai Junshi Bioscience Co., Ltd.; Qilu Pharmaceutical Co., Ltd.

Unknown

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer (BEVTOR)

MSS | pMMR | Refractory Metastatic Colorectal Cancer

China
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Active, not recruiting

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Locally Advanced/Metastatic HER2 Positive Solid Tumors

China, United States
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Healthy Volunteers

United States
Coherus Biosciences, Inc.

Completed

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

Immunity, Humoral

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1701 in Patients With Recurrent/Metastatic Scchn

Squamous Cell Carcinoma of Head and Neck

China
Cyclerion Therapeutics

Completed

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

Healthy

United States
Qilu Pharmaceutical Co., Ltd.

Unknown

Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

Healthy Males

China
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Advanced Solid Tumor

China
Qilu Pharmaceutical Co., Ltd.

Unknown

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

Postmenopausal Osteoporosis

China
Qilu Pharmaceutical Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Healthy People

China
Eisai Inc.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Breast Cancer

United States, Japan
National Cancer Institute (NCI)

Active, not recruiting

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Malignant Solid Neoplasm

United States
Qilu Pharmaceutical Co., Ltd.

Active, not recruiting

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Extensive-stage Small-cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Unknown

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

Healthy People

China
National Cancer Institute (NCI)

Terminated

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Cyclerion Therapeutics

Terminated

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Achalasia

United States
BioFirst Corporation
ABVC BioPharma, Inc

Suspended

Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

Retinal Detachment

Thailand, Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
Reata, a wholly owned subsidiary of Biogen

Completed

Safety and PK/PD of RTA 1701 in Healthy Adults

Healthy

Australia
Lysovant

Withdrawn

ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis (ERASE)

Endocarditis Infective | Bacteremia Due to Staphylococcus Aureus | Left Sided Infective Endocarditis (Disorder) | Right Sided Infective Endocarditis (Disorder)

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Gastric or Gastroesophageal Junction Cancer

China
National Cancer Institute (NCI)
NRG Oncology

Completed

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7

United States
Qilu Pharmaceutical Co., Ltd.

Unknown

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Bone Metastases

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

METASTATIC CERVICAL CANCER

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

Non-Small-Cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Colorectal Carcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Advanced Malignant Tumors

China
Qilu Pharmaceutical Co., Ltd.

Completed

Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

Wet Age-related Macular Degeneration

China
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Follicular Lymphoma | Marginal Zone Lymphoma | DLBCL | CLL | MCL | Indolent Lymphoma | Richter's Transformation | SLL | Mediastinal Large B-cell Lymphoma | Aggressive Lymphoma

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

China
Genelabs Technologies

Unknown

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

Lupus

United States, Mexico
Hunan Province Tumor Hospital

Recruiting

SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma (FLYFLY)

Non-Small Cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer

China
Genelabs Technologies

Completed

GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

Systemic Lupus Erythematosus

United States, Mexico
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Fudan University

Not yet recruiting

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

Australia, Poland
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Cervical Cancer

China
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Carcinoma, Non-Small-Cell Lung
Qilu Pharmaceutical Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
Qilu Pharmaceutical Co., Ltd.

Terminated

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
National Cancer Institute (NCI)

Terminated

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Ovarian Carcinoma

United States, Israel
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Yong Chen

Recruiting

To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma

United States, Canada, Puerto Rico

Search clinical trials for: QL1701

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations